leadf
logo-loader
viewAnteris Technologies Ltd
(
ASX:AVROTC:AMEUFFRA:DDF
)

Admedus Ltd moving up the value chain and preparing for 'pivotal' year

Wayne Paterson, chief executive of Admedus Ltd (ASX:AHZ), spoke to Proactive's Andrew Scott following the release of their quarterly update.

It's a big week for Admedus with the launch of both CardioCel in India and CardioCel 3D in North America.

CardioCel is the company’s flagship product and is becoming a surgeon-preferred biomaterial for heart valve repair surgeries.

Quick facts: Anteris Technologies Ltd

Follow
ASX:AVR

Price: 8.28 AUD

Market Cap: $66.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Anteris Technologies 'sitting on a significantly large opportunity' as it...

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson speaks to Proactive following the company's AGM. It's recently achieved a breakthrough in manufacturing the tissue used in ADAPT® treated products from bovine pericardium, after developing specialised machinery to create consistently thin...

on 15/7/21

2 min read